beauty

Page 5 of 512345

Has closed According to a release.

USD Underwriter exercises possibility of additional common shares[ Professional Services Close – Up] BuyBofA Merrill Lynch acted as sole book-running managers for the offering.Has closed According to a release, the issue of additional shares, and all shares were sold by MAP Pharmaceuticals. The total gross proceeds were approximately $ 59, and the total net proceeds of approximately U.S. $ 56, net of underwriting discounts and commissions..

MAP Pharmaceuticals is a biopharmaceutical company focuses on addressing the development and commercialization of novel therapies to patients’ needs in neurology focused.MAP Pharmaceuticals intends to use the proceeds from this offering for general corporate purposes and commercialization efforts for LEVADEX, orally inhaled orally inhaled investigational drug for the acute treatment of migraine. Source: St. Continue reading

Page 5 of 512345